Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 8449

Related Articles by Review for PubMed (Select 18773755)

1.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
2.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

PMID:
18426513
3.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

4.

Modern medical management of obesity: the role of pharmaceutical intervention.

Aronne LJ.

J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. Review.

PMID:
9787732
5.

New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

Scheen AJ, Ernest P.

Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Review.

6.

Effect of antiobesity medications in patients with type 2 diabetes mellitus.

Choussein S, Makri AA, Frangos CC, Petridou ET, Daskalopoulou SS.

Diabetes Obes Metab. 2009 Jul;11(7):641-64. doi: 10.1111/j.1463-1326.2008.01026.x. Epub 2009 Feb 18. Review.

PMID:
19236442
7.

[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].

Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C.

Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Review. French.

PMID:
16972542
8.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112
9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
10.

Pleiotropic effects of rimonabant: clinical implications.

Després JP.

Curr Pharm Des. 2009;15(5):553-70. Review.

PMID:
19199981
11.

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.

Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.

Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x. Review.

PMID:
20025693
12.

Rimonabant for the treatment of overweight and obese people.

Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N.

Health Technol Assess. 2009 Oct;13 Suppl 3:13-22. doi: 10.3310/hta13suppl3/03. Review.

13.

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.

Rubio MA, Gargallo M, Isabel Millán A, Moreno B.

Public Health Nutr. 2007 Oct;10(10A):1200-5. Review.

PMID:
17903331
14.

[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].

Zieba R.

Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26. Review. Polish.

15.

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A.

Health Technol Assess. 2012;16(5):iii-xiv, 1-195. doi: 10.3310/hta16050. Review.

16.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
17.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
18.

Pharmacological intervention: the antiobesity approach.

Rissanen A.

Eur J Clin Invest. 1998 Sep;28 Suppl 2:27-30. Review.

PMID:
9777325
19.

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

Viner RM, Hsia Y, Tomsic T, Wong IC.

Obes Rev. 2010 Aug;11(8):593-602. doi: 10.1111/j.1467-789X.2009.00651.x. Epub 2009 Nov 17. Review.

PMID:
19922432
20.

Pharmacological management of obesity.

Hanif MW, Kumar S.

Expert Opin Pharmacother. 2002 Dec;3(12):1711-8. Review.

PMID:
12472368
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk